268 related articles for article (PubMed ID: 34977528)
1. Cascade targeting codelivery of ingenol-3-angelate and doxorubicin for enhancing cancer chemoimmunotherapy through synergistic effects in prostate cancer.
Wang Z; Sun C; Wu H; Xie J; Zhang T; Li Y; Xu X; Wang P; Wang C
Mater Today Bio; 2022 Jan; 13():100189. PubMed ID: 34977528
[TBL] [Abstract][Full Text] [Related]
2. Sequential receptor-mediated mixed-charge nanomedicine to target pancreatic cancer, inducing immunogenic cell death and reshaping the tumor microenvironment.
Shen J; Sun C; Wang Z; Chu Z; Liu C; Xu X; Xia M; Zhao M; Wang C
Int J Pharm; 2021 May; 601():120553. PubMed ID: 33794325
[TBL] [Abstract][Full Text] [Related]
3. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
[TBL] [Abstract][Full Text] [Related]
4. Phosphorous Dendron Micelles as a Nanomedicine Platform for Cooperative Tumor Chemoimmunotherapy via Synergistic Modulation of Immune Cells.
Zhan M; Qiu J; Fan Y; Chen L; Guo Y; Wang Z; Li J; Majoral JP; Shi X
Adv Mater; 2023 Jan; 35(3):e2208277. PubMed ID: 36300810
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J
Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580
[TBL] [Abstract][Full Text] [Related]
6. A Novel Prostate-Specific Membrane-Antigen (PSMA) Targeted Micelle-Encapsulating Wogonin Inhibits Prostate Cancer Cell Proliferation via Inducing Intrinsic Apoptotic Pathway.
Zhang H; Liu X; Wu F; Qin F; Feng P; Xu T; Li X; Yang L
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27196894
[TBL] [Abstract][Full Text] [Related]
7. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel and Doxorubicin Codelivery by Nanocarriers for Synergistic Treatment of Prostate Cancer.
Li K; Zhan W; Chen Y; Jha RK; Chen X
Front Pharmacol; 2019; 10():1436. PubMed ID: 31920642
[TBL] [Abstract][Full Text] [Related]
9. Ingenol-3-Angelate Suppresses Growth of Melanoma Cells and Skin Tumor Development by Downregulation of NF-κB-Cox2 Signaling.
Wang D; Liu P
Med Sci Monit; 2018 Jan; 24():486-502. PubMed ID: 29368698
[TBL] [Abstract][Full Text] [Related]
10. Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma.
Yu Z; Guo J; Hu M; Gao Y; Huang L
ACS Nano; 2020 Apr; 14(4):4816-4828. PubMed ID: 32188241
[TBL] [Abstract][Full Text] [Related]
11. [Nanotechnology-mediated immunochemotherapy with Ingenol-3-Mebutate for Systematic Anti-tumor Effects].
Yu M; Zhao M; Yu R; Chu S; Xu J; Xia M; Wang C
J Control Release; 2019 Jun; 304():242-258. PubMed ID: 31071376
[TBL] [Abstract][Full Text] [Related]
12. Detachable Nanoparticle-Enhanced Chemoimmunotherapy Based on Precise Killing of Tumor Seeds and Normalizing the Growing Soil Strategy.
Wang L; Ding K; Zheng C; Xiao H; Liu X; Sun L; Omer R; Feng Q; Zhang Z
Nano Lett; 2020 Sep; 20(9):6272-6280. PubMed ID: 32787161
[TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade.
Zhou F; Feng B; Yu H; Wang D; Wang T; Ma Y; Wang S; Li Y
Adv Mater; 2019 Apr; 31(14):e1805888. PubMed ID: 30762908
[TBL] [Abstract][Full Text] [Related]
14. Heating tumors with tumor cell-derived nanoparticles to enhance chemoimmunotherapy for colorectal cancer.
Li XY; Li RH; Cong JZ; Liu WS; Zhang Y; Guan HL; Zhu LL; Chen K; Pang LY; Jin H
Nanomedicine (Lond); 2024 Mar; 19(7):561-579. PubMed ID: 38265008
[No Abstract] [Full Text] [Related]
15. Smart pH-Responsive Nanocube-Controlled Delivery of DNA Vaccine and Chemotherapeutic Drugs for Chemoimmunotherapy.
Duong HTT; Thambi T; Yin Y; Lee JE; Seo YK; Jeong JH; Lee DS
ACS Appl Mater Interfaces; 2019 Apr; 11(14):13058-13068. PubMed ID: 30888149
[TBL] [Abstract][Full Text] [Related]
16. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
17. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
[TBL] [Abstract][Full Text] [Related]
18. RasGRPs are targets of the anti-cancer agent ingenol-3-angelate.
Song X; Lopez-Campistrous A; Sun L; Dower NA; Kedei N; Yang J; Kelsey JS; Lewin NE; Esch TE; Blumberg PM; Stone JC
PLoS One; 2013; 8(8):e72331. PubMed ID: 23991094
[TBL] [Abstract][Full Text] [Related]
19. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death.
Choi Y; Yoon HY; Kim J; Yang S; Lee J; Choi JW; Moon Y; Kim J; Lim S; Shim MK; Jeon S; Kwon IC; Kim K
Pharmaceutics; 2020 Nov; 12(12):. PubMed ID: 33260446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
